The nonprofit organization Accelerated Cure Project for Multiple Sclerosis is going to sponsor the launch of the Optimizing Treatment – Understanding Progression (OPT-UP) study in collaboration with biopharmaceutical company EMD Serono, Inc, a subsidiary of the german Merck KGaA. The study will enroll 2,500 MS patients, which will be followed for five years in order to understand the main treatment outcomes suffered.
The new agreement is aimed at supporting the creation of a database of the factors that afflict MS patients regarding treatment outcomes through a U.S.-based, multicenter longitudinal clinical research. The purpose of the study is to help physicians in their therapeutic decisions and interventions, as well as provide knowledge and tolls for the development of new strategies and treatments for MS.
“We have been working diligently with leading MS clinicians, people living with MS, biopharma companies, and foundations to design a study that addresses the most critical medical needs in MS today,” stated the president and CEO of the Accelerated Cure Project for MS, Robert McBurney. “We are thrilled that EMD Serono, a leader in the area of MS therapeutics, has chosen to take a lead founding sponsor role, providing the support needed to implement this important study.”
~~~~~~~~~~~~~~~~~~~~
Keep CURRENT and up to date, with MS News and Information
Sign-up for emails
.
WATCH OUR MS EDUCATIONAL VIDEOS by Topic,
found here: www.youtube.com/msviewsandnews
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews